Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (NASDAQ: ARQT) has granted a total of 26,500 restricted stock units (RSUs) to three newly hired employees. The awards were approved by the company's Compensation Committee and granted under the Arcutis Biotherapeutics 2022 Inducement Plan on May 1, 2025. The RSUs will vest over a four-year period, with 25% vesting on each annual anniversary of the vesting commencement date, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new employees joining the company.
Arcutis Biotherapeutics (NASDAQ: ARQT) ha assegnato un totale di 26.500 unità di azioni vincolate (RSU) a tre nuovi dipendenti assunti. I premi sono stati approvati dal Comitato per la Retribuzione della società e concessi nell'ambito del Piano di Incentivazione Arcutis Biotherapeutics 2022 il 1° maggio 2025. Le RSU matureranno in un periodo di quattro anni, con il 25% che matura ogni anniversario annuale della data di inizio maturazione, subordinatamente alla continuità dell'impiego. Questa concessione è stata effettuata in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per i nuovi dipendenti che si uniscono all'azienda.
Arcutis Biotherapeutics (NASDAQ: ARQT) ha otorgado un total de 26,500 unidades restringidas de acciones (RSU) a tres empleados recién contratados. Los premios fueron aprobados por el Comité de Compensación de la empresa y otorgados bajo el Plan de Incentivos de Arcutis Biotherapeutics 2022 el 1 de mayo de 2025. Las RSU se consolidarán durante un período de cuatro años, con un 25% consolidándose en cada aniversario anual de la fecha de inicio de consolidación, condicionado a la continuidad del empleo. Esta concesión se realizó de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivo para los nuevos empleados que se incorporan a la empresa.
Arcutis Biotherapeutics (NASDAQ: ARQT)는 새로 채용된 세 명의 직원에게 총 26,500개의 제한 주식 단위(RSU)를 부여했습니다. 이 보상은 회사의 보상 위원회에서 승인되었으며, 2025년 5월 1일에 Arcutis Biotherapeutics 2022 유인 계획에 따라 부여되었습니다. RSU는 4년 동안 점진적으로 취득되며, 취득 시작일 매년 기념일마다 25%씩 취득되며, 계속 고용 조건이 충족되어야 합니다. 이 부여는 신규 직원 유치를 위한 유인책으로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Arcutis Biotherapeutics (NASDAQ : ARQT) a attribué un total de 26 500 unités d'actions restreintes (RSU) à trois nouveaux employés embauchés. Ces attributions ont été approuvées par le comité de rémunération de la société et accordées dans le cadre du Plan d'Induction Arcutis Biotherapeutics 2022 le 1er mai 2025. Les RSU seront acquises sur une période de quatre ans, avec 25 % acquises à chaque anniversaire annuel de la date de début d'acquisition, sous réserve d'une continuité d'emploi. Cette attribution a été réalisée conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation pour les nouveaux employés rejoignant la société.
Arcutis Biotherapeutics (NASDAQ: ARQT) hat insgesamt 26.500 Restricted Stock Units (RSUs) an drei neu eingestellte Mitarbeiter vergeben. Die Zuteilungen wurden vom Vergütungsausschuss des Unternehmens genehmigt und am 1. Mai 2025 im Rahmen des Arcutis Biotherapeutics 2022 Inducement Plans gewährt. Die RSUs werden über einen Zeitraum von vier Jahren vesten, wobei jeweils 25 % an jedem jährlichen Jahrestag des Vesting-Beginns unter der Voraussetzung kontinuierlicher Beschäftigung vesten. Diese Gewährung erfolgte gemäß Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die neuen Mitarbeiter, die dem Unternehmen beitreten.
- None.
- None.
WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 26,500 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of May 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Corporate Controller
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant in May 2025?
What is the vesting schedule for ARQT's May 2025 restricted stock units grant?
Under which plan were the ARQT restricted stock units granted in May 2025?
Why did Arcutis Biotherapeutics issue these restricted stock units in May 2025?
